Disclosure according to Article 5 of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052
Disclosure according to Article 5 of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052
In the period from May 24 up to and including May 28, 2021, a total of 2.631 shares of AlzChem Group AG were acquired as part of the share buyback program announced on February 2, 2021. The total number of shares acquired to date as part of this buyback amounts to 25.982. The acquisition was carried out by ODDO BHF Aktiengesellschaft, Frankfurt am Main/Germany via the stock exchange (XETRA) on behalf of AlzChem Group AG.
The total number of repurchased shares, the weighted average price and the aggregated volume per day were as follows:
| Buyback date | Total number of shares | Weighted average price (EUR) | Aggregated volume (EUR) |
|---|---|---|---|
| 26.05.2021 | 1.253 | 25,0160 | 31.345,00 |
| 27.05.2021 | 1.204 | 24,8517 | 29.921,50 |
| 28.05.2021 | 174 | 24,9000 | 4.332,60 |
| Σ | 2.631 | 24,9331 | 65.599,10 |
This information as well as the detailed information on the individual daily transactions related to the buy-back program are also published on the Company's website at https://www.alzchem.com/de/investor-relations/stock/share-buy-back in accordance with Art. 2 par. 3 sentence 2 of Delegated Regulation (EU) 2016/1052.
Trostberg, May 31, 2021
AlzChem Group AG
About AlzChem
AlzChem is a globally active specialty chemicals company that is one of the market leaders in its fields of activity, also in the international segment. With its broad product range, AlzChem benefits in a special way from the four very different global megatrends of energy efficiency, sustainability, healthy aging and population growth, insofar as efficiency in food production can be decisively improved. Here, AlzChem products offer attractive solutions in a wide range of different applications.
The company sees interesting growth prospects for itself in particular in the areas of human and animal nutrition, pharmaceuticals, agriculture, fine chemicals, metallurgy and renewable energies. The company’s broad product range includes dietary supplements, plant growth regulators and precursors for corona tests.
AlzChem employs around 1,630 people at four production sites in Germany and Sweden, and at two sales companies in the USA and China. In 2020, AlzChem generated consolidated sales of around EUR 379 million and EBITDA of around EUR 53.8 million.
Contact
Sabine Sieber
Head of Investor Relations & Communications
Alzchem Group AG
Dr.-Albert-Frank-Str. 32
83308 Trostberg
Germany